Nurse Practitioner · Boston, MA
NPI
1730446634
Since 2012
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
0 Emerson Pl Ste 118
Boston, MA, 02114
Phone (617) 724-1124
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
390 services
Medicare patients, 2024
73
Average age 71
Drug cost, 2024
$4.5M
1,750 prescriptions
Company payments, 2025
$239
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Meredith L Saylor was code 99215 (office e&m - established), 208 times for 60 patients. In total Meredith L Saylor billed 390 services in 5 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 208 | 60 | $98.69 | $21K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 127 | 39 | $11.74 | $1,491 |
| 99214 Office E&M - Established | Facility | 29 | 22 | $68.89 | $1,998 |
| 38222 Other Organ Systems | Facility | 16 | 16 | $53.08 | $849 |
By year: 2022 $16K for 223 services; 2023 $25K for 311 services; 2024 $26K for 390 services.
Medicare prescription drug claims, 2024
In 2024, the drug Meredith L Saylor prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 213 prescriptions and refills. In total Meredith L Saylor wrote 1,750 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 213 | 213 | 37 | $2.8M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 163 | 188 | 32 | $1,058 |
| Acyclovir Generic | 101 | 202 | 31 | $1,773 |
| Famciclovir Generic | 101 | 178 | 28 | $6,076 |
| Atorvastatin Calcium Generic | 59 | 136 | 18 | $487 |
| Ursodiol Generic | 54 | 84 | 21 | $6,127 |
| Omeprazole Generic | 46 | 118 | 15 | $534 |
| Prednisone Generic | 38 | 57 | 17 | $437 |
| Gabapentin Generic | 37 | 46 | Under 11 | $426 |
| Rezurock Belumosudil Mesylate | 36 | 36 | Under 11 | $668K |
| Atovaquone Generic | 34 | 38 | 14 | $15K |
| Amlodipine Besylate Generic | 32 | 75 | 13 | $144 |
| Allopurinol Generic | 31 | 61 | Under 11 | $255 |
| Eliquis Apixaban | 29 | 37 | Under 11 | $21K |
| Lorazepam Generic | 29 | 29 | 11 | $108 |
Brand drugs: - claims; generic drugs: 1,319 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Meredith L Saylor $239 ($239 in general payments such as food, travel and fees) from 4 companies. The largest payer was Incyte Corporation with $155.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.